Business Description
Chengdu Kanghua Biological Products Co Ltd
ISIN : CNE100003Y57
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.03 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.33 | |||||
Interest Coverage | 131.07 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 10.39 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.3 | |||||
3-Year EBITDA Growth Rate | 3.9 | |||||
3-Year EPS without NRI Growth Rate | 6 | |||||
3-Year FCF Growth Rate | 16.3 | |||||
3-Year Book Growth Rate | 21.3 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 75.21 | |||||
9-Day RSI | 62.65 | |||||
14-Day RSI | 56.04 | |||||
6-1 Month Momentum % | -12.34 | |||||
12-1 Month Momentum % | -34.97 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.49 | |||||
Quick Ratio | 4.17 | |||||
Cash Ratio | 1.8 | |||||
Days Inventory | 694.05 | |||||
Days Sales Outstanding | 304.61 | |||||
Days Payable | 106.71 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.84 | |||||
Dividend Payout Ratio | 0.11 | |||||
Forward Dividend Yield % | 0.84 | |||||
5-Year Yield-on-Cost % | 0.84 | |||||
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | 0.32 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 93.97 | |||||
Operating Margin % | 42.24 | |||||
Net Margin % | 34.37 | |||||
FCF Margin % | 32.48 | |||||
ROE % | 16.34 | |||||
ROA % | 13.92 | |||||
ROIC % | 21.85 | |||||
ROC (Joel Greenblatt) % | 30.16 | |||||
ROCE % | 18.63 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 14.59 | |||||
PE Ratio without NRI | 13.42 | |||||
Price-to-Owner-Earnings | 22.6 | |||||
PEG Ratio | 0.57 | |||||
PS Ratio | 5.01 | |||||
PB Ratio | 2.26 | |||||
Price-to-Tangible-Book | 2.28 | |||||
Price-to-Free-Cash-Flow | 15.43 | |||||
Price-to-Operating-Cash-Flow | 12.32 | |||||
EV-to-EBIT | 11.31 | |||||
EV-to-EBITDA | 11.31 | |||||
EV-to-Revenue | 4.46 | |||||
EV-to-FCF | 13.72 | |||||
Price-to-Projected-FCF | 2.26 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.54 | |||||
Price-to-Graham-Number | 1.17 | |||||
Price-to-Net-Current-Asset-Value | 4.01 | |||||
Price-to-Net-Cash | 17.88 | |||||
Earnings Yield (Greenblatt) % | 8.84 | |||||
FCF Yield % | 6.43 | |||||
Forward Rate of Return (Yacktman) % | 21.27 |